ALOX5 promoter genotype and response to montelukast in moderate persistent asthma
ALOX5 promoter genotype and response to montelukast in moderate persistent asthma
复制标题
DOI：
10.1016/j.rmed.2008.01.011
复制
发表时间：
2008-06-01
影响因子：
4.3
通讯作者：
Diez, Ignacio
中科院分区：
文献类型：
--
作者：
Telleria, Juan J.;Blanco-Quiros, Alfredo;Diez, Ignacio
背景资料：据推测，突变等位基因的白三烯通路的哮喘患者不应响应白三烯受体拮抗剂和量身定制的治疗的概念越来越supported.Methods：61例（平均年龄24.9岁，范围14-52）与中度持续性哮喘的临床和免疫学评估之前和之后6个月的孟鲁司特治疗。结果：ALOX 5基因启动子区（-147 ~-176）串联重复多态性纯合型32例（52.5%），杂合型17例（27.9%），4/4重复型12例（19.7%）。孟鲁司特治疗后，在5/5或4/5重复的患者中观察到哮喘急性发作次数减少，FEV 1改善和β 2受体激动剂使用减少。相反，4/4重复基因型患者治疗后没有修改这些data.Conclusions：它被证实，ALOX 5启动子多态性有明确的影响在特应性中度持续性哮喘患者的孟鲁司特反应。遗传学研究可以确定那些最有可能对孟鲁司特产生反应的患者。(C)2008爱思唯尔有限公司保留所有权利。
Background: It was hypothesized that asthmatic patients with mutant alleles in the leukotriene pathway should not respond to leukotriene receptor antagonists and the concept of a tailored treatment is increasingly supported.Methods: Sixty-one patients (mean age 24.9 years, range 14-52) with moderate persistent asthma were clinical and immunological assess prior and after a 6-month treatment with montelukast. Tandem repeat polymorphisms were genotyped in the promoter (-147 to -176) of 5-lipoxygenase gene (ALOX5).Results: Thirty-two patients (52.5%) were homozygous for the five repeats allele; 17 (27.9%) were heterozygous (4/5 repeats) and 12 (19.7%) were homozygous for 4/4 repeats. After the montelukast treatment decrease number of asthma exacerbations, improvement of FEV1 and decreased use of beta(2) agonists was observed in patients with 5/5 or 4/5 repeats. Conversely, the patients with 4/4 repeats genotype did not modify these data after treatment.Conclusions: It was confirmed that ALOX5 promoter polymorphisms have a clear influence in montelukast response in atopic moderate persistent asthma patients. The genetic study could identify those patients most likely to respond to montelukast. (C) 2008 Elsevier Ltd. All rights reserved.